Brought to you by 
Pfizer spin-off RaQualia gets $84mm in funding
Jul 2008
Executive Summary
Pfizer spun off RaQualia Pharma, which gets a combined $63mm from top shareholder NIF SMBC Ventures (holds a 32% stake) and Coller Capital (24% ownership) in addition to $21mm from Pfizer for a 19% stake. Seven other investors are backing RaQualia as well.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer spin-off RaQualia gets $84mm in funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice